Supernus Pharmaceuticals SUPN Finished goods
Finished goods at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's finished goods.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's finished goods?
- Supernus Pharmaceuticals (SUPN) reported finished goods of $19.54M in Q1 2026.
- How has Supernus Pharmaceuticals's finished goods changed year-over-year?
- Supernus Pharmaceuticals's finished goods decreased by 11.5% year-over-year, from $22.07M to $19.54M.
- What is the long-term trend for Supernus Pharmaceuticals's finished goods?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's finished goods has grown at a 4.3% compound annual growth rate (CAGR), from $17.13M to $21.12M.
- What does finished goods mean?
- Completed products ready for sale, valued at the lower of cost or net realizable value.